Chemomab Therapeutics Ltd. SEC filings CMMB
Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 30, 2026 | — |
| DRS | Filing | Aug 12, 2026 | — |
| EFFECT | Filing | Dec 10, 2024 | — |
| EFFECT | Filing | Sep 6, 2024 | — |
| CORRESP | Letter to the SEC | Sep 4, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2024 | — |
| D | Filing | Aug 9, 2024 | — |
| EFFECT | Filing | Nov 3, 2023 | — |
| CORRESP | Letter to the SEC | Nov 1, 2023 | — |
| RW | Filing | Jun 2, 2023 | — |
| EFFECT | Filing | May 17, 2021 | — |
| CORRESP | Letter to the SEC | May 12, 2021 | — |
| UPLOAD | Letter from the SEC | May 5, 2021 | — |
| EFFECT | Filing | Apr 28, 2021 | — |
| CORRESP | Letter to the SEC | Apr 26, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2021 | — |
| D | Filing | Mar 30, 2021 | — |
| 425 | Form 8-k | Mar 10, 2021 | — |
| 425 | Filing | Mar 9, 2021 | — |
| EFFECT | Filing | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| 425 | Form 8-k | Feb 8, 2021 | — |
| 425 | Filing | Feb 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2021 | — |
| 425 | Filing | Jan 11, 2021 | — |
| 425 | Filing | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2020 | — |
| CORRESP | Letter to the SEC | Apr 6, 2020 | — |
| CT ORDER | Filing | Feb 12, 2019 | — |
| EFFECT | Filing | Feb 11, 2019 | — |
| CERT | Filing | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| 8-A12B | Filing | Feb 8, 2019 | — |
| CORRESP | Letter to the SEC | Feb 7, 2019 | — |
| CORRESP | Letter to the SEC | Feb 7, 2019 | — |
| CORRESP | Letter to the SEC | Feb 7, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 4, 2019 | — |
| CORRESP | Letter to the SEC | Jan 7, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2018 | — |
| DRS/A | Filing | Nov 27, 2018 | — |
| DRSLTR | Filing | Nov 26, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2018 | — |
| DRS | Filing | Sep 28, 2018 | — |
| DRS/A | Filing | Nov 3, 2015 | — |
| DRS | Filing | Sep 22, 2015 | — |
| 15-15D | Filing | Jan 2, 2013 | — |
| EFFECT | Filing | Dec 18, 2012 | — |
| EFFECT | Filing | Jun 7, 2012 | — |
| 425 | Form 425 | Nov 7, 2011 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534248
- Former names
- Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.